Optimizing Helical Tomotherapy for Left-Sided Breast Cancer: A Retrospective Dosimetric Study of a Novel Virtual Organ-Arc Block

优化左侧乳腺癌螺旋断层放射治疗:一种新型虚拟器官弧阻挡器的回顾性剂量学研究

阅读:2

Abstract

IntroductionLeft-sided breast cancer radiotherapy requires precise dose modulation to balance target coverage and organ-at-risk (OAR) sparing. This study evaluates a novel Organ and Arc-based Directional Block (OABD Block) in helical tomotherapy planning to address this challenge.MethodsIn this single-institutional retrospective study, 10 post-mastectomy patients with left-sided breast cancer receiving adjuvant radiotherapy were studied. Target volumes included chest wall, internal mammary, axillary, and supraclavicular lymph nodes, with a dose of 50 Gy over 25 fractions. Using a tomotherapy planning system, an OABD Block was configured to incorporate arc structures and protect organs-at-risk. For each patient, helical tomotherapy plans were prepared with and without the OABD Block, keeping field width, pitch, and modulation factors identical. Additionally, static intensity-modulated radiotherapy (IMRT) plans were created on a United Imaging system. Treatment plans were evaluated by dose-volume parameters, conformity and homogeneity indices, and mean doses to targets and normal tissues.ResultsHelical tomotherapy with the OABD Block provided a mean conformity Index of 0.79 for the Planning Target Volume, higher than plans without the block (0.73) but below IMRT plans (0.88). The homogeneity Index averaged 0.14 with the block, 0.18 without, and 0.11 in IMRT. For the internal mammary lymph node region, D95% reached 5007.7 cGy with the block, compared to 5001.1 cGy without and 4897.9 cGy in IMRT. The OABD Block reduced the mean heart dose to 478.7 cGy, compared to 533.5 cGy without and 638.9 cGy in IMRT. Left lung V5 was 48.0% with the block, 52.7% without, and 53.2% in IMRT; V20 was also lowest with the block (17.5%) versus without (20.3%) and IMRT (24.3%).ConclusionAdding the OABD Block to helical tomotherapy improved internal mammary lymph node dose coverage and reduced exposure to organs at risk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。